Bayer’s Two?Front Battle: Legal Relief Gathers Pace, but the Balance Sheet Is Still Under Scrutiny
Published on 07/20/2026 at 12:12 | Redaktion boerse-global.de
The past few weeks have delivered a flurry of positive news for Bayer – a landmark US Supreme Court ruling, a wave of analyst upgrades, and a multi?billion?euro asset sale – yet a critical piece of the legal puzzle remains unresolved. The fairness hearing to finalise the $7.25?billion glyphosate class?action settlement, originally set for early July, was postponed by a Missouri court to 19?August 2026. The delay is relatively short, but it pushes the decision into an already busy window for the German conglomerate, coming just two weeks after its first?half earnings report on 4?August.
The Supreme Court’s 7?2 decision in the “Durnell” case at the end of June has already reshaped the legal landscape. By ruling that federal law pre?empts state?level cancer?warning requirements on pesticide labels approved by the EPA, the judgment undercuts thousands of pending glyphosate claims. That shift has triggered a wave of analyst upgrades. Barclays raised its price target from €50 to €60 on 14?July and reiterated an “Overweight” rating, while JPMorgan reaffirmed its “Overweight” stance on 17?July, citing the improved risk profile. Berenberg’s Sebastian Bray followed on 7?July, lifting his target from €40.50 to €55 but keeping a “Hold” rating, and he floated the possibility of a partial IPO for Bayer’s Monsanto business as a strategic option.
Yet not all analysts are swept up in the optimism. Jefferies’ Michael Leuchten held his target at €46 and a “Hold” rating on 13?July, arguing that strengthening the balance sheet must come before any talk of a break?up. That caution echoes the view of Fitch Ratings, which on the same day affirmed Bayer’s BBB long?term issuer rating but kept a “Negative” outlook, pointing to high net debt and projected cash outflows of €4?billion to €5?billion for litigation costs this year alone.
Should investors sell immediately? Or is it worth buying Bayer?
Bayer is taking concrete steps to address the debt burden. Media reports indicate the company is selling its contraception business for roughly €3?billion, a move that would directly reduce net financial debt and help cushion litigation expenses. Separately, on 15?July it placed $5?billion in new US?dollar bonds, which the group said was well received by the capital market. These efforts run alongside operational restructuring: in early July Bayer bundled the US glyphosate pricing and production operations into a new subsidiary called Ruveon, based in St.?Louis. On the other side of the legal ledger, its Bayer CropScience unit is fighting a patent?licensing lawsuit filed by Latham Seed Company; Bayer moved to dismiss the case on 13?July.
Further legal progress came on the individual case level. The Philadelphia Court of Common Pleas granted several Bayer motions in the “Purnell” case, delaying a trial originally slated for July – another victory that buys time in a proceeding already weakened by the Supreme Court’s broader ruling.
Beyond the courtroom, Bayer is also laying groundwork for the long?term future of its agriculture business. Mid?July saw an exclusive licensing agreement with French seed breeder RAGT to develop hybrid wheat for Europe and North America. Commercialisation is not expected until the early 2030s, so the deal has limited near?term impact, but it underscores that the group is thinking strategically beyond the glyphosate saga.
The share price has absorbed this mix of news. On Friday the stock closed at €48.06, up 29.86% year?to?date. That still leaves it 10.77% below the 52?week high of €53.86 set on 3?July. With the half?year report due on 4?August, the postponed settlement hearing on 19?August, and an investor event for the Crop Science division scheduled for 2?September, the next six weeks will test whether the legal tailwinds can offset the persistent drag from debt and litigation costs.
Ad
Bayer Stock: New Analysis - 20 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
